Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: TEColeman who wrote (767)	8/15/1998 3:57:00 PM
From: Richard Haugland	Read Replies (1) \| Respond to of 1728

There is a good article in Nature Biotechnology 16, 725 (1998) (August) on DNA diagnostics, including strategies of some companies to get around both PCR and AFFX patents. It mentions the PCR patents and Ed Southern patents as being obstacles for most companies (I believe that AFFX is the only company that is OK on both of these now). Companies mentioned include some familiar ones: Nanogen (with Becton Dickinson) Hyseq (with Perkin Elmer) and some relatively unfamiliar ones: Molecular Tool (using arrays of all 4, 5 and base length oligos, although I thought this covered generically by a recent AFFX patent, at least for high density arrays) Cepheid (using automated fluorescence PCR on a chip) Micronics (using fluidics on a chip) Clinical Micro Sensors (presumably using direct electronic detection of the hybridization step!) Atom Sciences (using PCR and mass spec with peptide nucleic acids) Sequenon (in Germany using mass spec) Gamera (using compact disks (CDs) on a disk player!)